Amide-Substituted Indazole Salts for Selective PARP Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARP inhibitors have weak inhibitory activity and often exhibit effects unrelated to PARP inhibition, necessitating the development of potent inhibitors targeting poly(ADP-ribose)polymerase (PARP) enzymes, particularly for treating cancers with DNA-repair defects and conditions like stroke, inflammation, and chemotherapy toxicity.
Innovation Solution
The development of amide-substituted indazole compounds, specifically pharmaceutically acceptable salts such as (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium salts, which exhibit high inhibition of PARP-1 and PARP-2 activity, demonstrating strong anti-proliferative effects in BRCA1 and BRCA2 deficient cell lines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PARP inhibitors are used, then they can target PARP enzymes, but they exhibit weak inhibitory activity and often show effects unrelated to PARP inhibition
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PARP inhibitors through amide-substituted indazole scaffolds and varying substituent patterns (R1-R6 positions) to achieve potent and selective PARP inhibition. This structural optimization transforms weak inhibitors into compounds with high inhibitory activity while reducing off-target effects.
2Reliability
If potent PARP inhibitors are developed, then they can effectively treat cancers with DNA-repair defects, but they may increase toxicity to normal cells
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns at different positions (R1-R6) of the indazole scaffold to achieve selective toxicity. The amide substitution and specific stereochemistry ((3S)-configuration) create localized interactions that enhance anti-proliferative effects in BRCA-deficient cells while sparing normal cells with intact DNA repair mechanisms.
3Productivity
If PARP inhibitors are used to enhance cancer treatment efficacy, then they can work synergistically with chemotherapy and radiotherapy, but they may amplify normal tissue damage
Solution Approach 1:
The patent applies partial or excessive action by using PARP inhibitors at optimized dosages that achieve sufficient PARP inhibition to enhance cancer treatment efficacy without completely depleting PARP activity in normal tissues. This partial inhibition strategy maintains enough PARP function in healthy cells to prevent excessive toxicity while providing sufficient inhibition in cancer cells with defective DNA repair pathways.
Data Source
AI summary
The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA -damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.